AnorMED Inc. Form SC 13D/A November 09, 2006

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13D/A

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(AMENDMENT NO. 1) *

AnorMED Inc.
(Name of Issuer)
Common Shares Without Par Value
(Title of Class of Securities)
035910108
(CUSIP Number)

Brett Spector
SuttonBrook Capital Management LP
598 Madison Avenue
6th Floor
New York, NY 10022
(212) 588-6622

(Name, Address and Telephone Number of Persons Authorized to Receive Notices and Communications)

November 7, 2006

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box $|_|$.

*The remainder of this cover page will be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but will be subject to all other provisions of the Act (however, see the Notes).

	SCHEDULE 13D	
CUSIP No. 035910108		Page 2 of 8

	EPORTING PERSON ENTIFICATION NO. OF ABOVE PERSON	
SUT	TONBROOK CAPITAL MANAGEMENT LP	
2 CHECK THE	APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) _ (b) _
3 SEC USE C	NLY	
4 SOURCE OF	FUNDS	
AF		
	IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED TO ITEMS 2(d) or 2(e)	_
6 CITIZENSH	IP OR PLACE OF ORGANIZATION	
DEL	AWARE	
NUMBER OF	7 SOLE VOTING POWER	
SHARES	0	
BENEFICIALLY	8 SHARED VOTING POWER	
OWNED BY	0	
	9 SOLE DISPOSITIVE POWER	
EACH REPORTING	0	
	10 SHARED DISPOSITIVE POWER	
WITH	0	
11 AGGREGATE 0	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES HARES	I_I
	F CLASS REPRESENTED BY AMOUNT IN ROW (11)	

0%

14 TYPE OF	REPORT	ING PERSON		
PN	1			
		SCHEDULE 13D		
CUSIP No. 03591	 L0108		Page 3 of 8	
		ING PERSON ICATION NO. OF ABOVE PERSON		
St	JTTONBR	OOK CAPITAL PORTFOLIO L.P.		
2 CHECK TH	 HE APPR	OPRIATE BOX IF A MEMBER OF A GROUP		a) _ b) _
3 SEC USE	ONLY			
4 SOURCE C	OF FUND	S		
WC	C, 00			
		ISCLOSURE OF LEGAL PROCEEDINGS IS RECEMBER 2(d) or 2(e)	 QUIRED	_
6 CITIZENS	 SHIP OR	PLACE OF ORGANIZATION		
CF	AYMAN I	SLANDS		
NUMBER OF	7	SOLE VOTING POWER		
SHARES		0		
BENEFICIALLY	8	SHARED VOTING POWER		
OWNED BY		0		
EACH	9	SOLE DISPOSITIVE POWER		
REPORTING		0		
PERSON	 1 0	SHARED DISPOSITIVE POWER		
WITH	± 0	O O		

11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	0	
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES	_
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)	
	0%	
14	TYPE OF REPORTING PERSON	
	PN	
	SCHEDULE 13D	
	SIP No. 035910108 Page 4 of 8	
1	NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON	
	JOHN LONDON	
2) _
3	SEC USE ONLY	
4	SOURCE OF FUNDS	
	AF	
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)	_
6	CITIZENSHIP OR PLACE OF ORGANIZATION	
	UNITED STATES	
	7 SOLE VOTING POWER NUMBER OF	
	NUMBER OF 0 SHARES	

BENE	EFICIALLY	SHARED VOTING POW	IER		
OV	NNED BY	0			
	EACH	SOLE DISPOSITIVE	POWER		
REI	PORTING	0			
Ε	PERSON	LO SHARED DISPOSITIV	ZE POWER		
	WITH	0			
11	AGGREGATE	AMOUNT BENEFICIALLY OWN	IED BY EACH REPORTING PERSON		
	0				
12		IF THE AGGREGATE AMOUNT		_	
13	PERCENT O	CLASS REPRESENTED BY A	MOUNT IN ROW (11)		
	0%				
		PORTING PERSON			
	IN				
		SCHEDULE	13D		
	No. 035910	J8 	Page 5 o	I 8 	
1		PORTING PERSON NTIFICATION NO. OF ABOV	E PERSON		
	STE	EN M. WEINSTEIN			
2	CHECK THE	APPROPRIATE BOX IF A ME	:MBER OF A GROUP	(a) _ (b) _	
3	SEC USE O	LY			
4	SOURCE OF	FUNDS			
	AF				

	IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED TO ITEMS 2(d) or 2(e)	_	
6 CITIZENSH	CITIZENSHIP OR PLACE OF ORGANIZATION		
UNI	TED STATES		
NUMBER OF	7 SOLE VOTING POWER		
SHARES	0		
BENEFICIALLY	8 SHARED VOTING POWER		
OWNED BY	0		
EACH	9 SOLE DISPOSITIVE POWER		
REPORTING	0		
	10 SHARED DISPOSITIVE POWER		
WITH	0		
11 AGGREGATE	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
0			
12 CHECK BOX CERTAIN S.	IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES HARES	_	
13 PERCENT O	F CLASS REPRESENTED BY AMOUNT IN ROW (11)		
0%			
14 TYPE OF R	EPORTING PERSON		
IN			

This Amendment No. 1 to Schedule 13D amends certain information contained in the Schedule 13D dated September 27, 2006 and filed on September 27, 2006 (the "Schedule 13D") by SuttonBrook Capital Management LP (the "Investment Manager"), SuttonBrook Capital Portfolio L.P. (the "Master Fund"), John London ("Mr. London") and Steven M. Weinstein ("Mr. Weinstein" and, together with the Investment Manager, the Master Fund and Mr. London, the "Filing Persons") relating to the common shares without par value (the "Common Stock"), of AnorMED Inc., a Canadian corporation (the "Company"). Capitalized terms used but not defined herein have the meanings ascribed to them in the Schedule 13D.

ITEM 5. INTERESTS IN SECURITIES OF THE ISSUER.

Item 5 is amended as follows:

- (a) As of November 7, 2006, the Filing Persons are no longer beneficial owners of any shares of Common Stock.
- (b) As of November 7, 2006, none of the Filing Persons have the power to vote or direct the vote with respect to, or to dispose or direct the disposition of, any shares of Common Stock.
- (c) On November 7, 2006, each of the Filing Persons tendered its shares of Common Stock into the tender offer by Dematal Corp, a Nova Scotia unlimited company and a wholly-owned subsidiary of Genzyme Corporation, a Massachusetts corporation at a price of \$13.50 per share of Common Stock. Genzyme Corporation announced on November 7, 2006 that all shares of Common Stock tendered into the tender offer were accepted for payment. Upon such acceptance, the Filing Persons ceased to own, beneficially or otherwise, any shares of Common Stock.
 - (d) Not applicable.
- (e) As of November 7, 2006, the Filing Persons are no longer beneficial owners of any shares of Common Stock. Accordingly, this amendment is the final amendment to Schedule 13D.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

November 9, 2006

SuttonBrook Capital Management LP

By: SuttonBrook Holdings LLC, Its General Partner

By: /s/ John London

Name: John London Title: Managing Member

SuttonBrook Capital Portfolio L.P.

By: SuttonBrook Capital Partners LP,
Its General Partner

By: SuttonBrook Capital Associates LP,
Its General Partner

By: SuttonBrook Capital Associates LLC,
Its General Partner

By: /s/ John London

Name: John London Title: Managing Member

/s/ John London

John London

/s/ Steven M. Weinstein

Steven M. Weinstein

EXHIBIT 1 - JOINT FILING AGREEMENT

Joint Filing Agreement

The undersigned hereby agree that this Amendment No. 1 to Schedule 13D filed herewith relating to the common shares without par value of AnorMED Inc., is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(k) (1) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersigned.

This Agreement may be executed in counterparts and each of such counterparts taken together shall constitute one and the same instrument.

November 9, 2006

SuttonBrook Capital Management LP

By: SuttonBrook Holdings LLC, Its General Partner

By: /s/ John London

Name: John London
Title: Managing Member

SuttonBrook Capital Portfolio L.P.

By: SuttonBrook Capital Partners LP,

Its General Partner

By: SuttonBrook Capital Associates LP,

Its General Partner

By: SuttonBrook Capital Associates LLC,

Its General Partner

By: /s/ John London

Name: John London Title: Managing Member

/s/ John London

John London

/s/ Steven M. Weinstein
-----Steven M. Weinstein